Literature DB >> 21213127

Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group.

Minoru Yoshida1, Nobu Akiyama, Hiroyuki Fujita, Katsuhiro Miura, Jun-ichi Miyatake, Hiroshi Handa, Katsuyuki Kito, Masatomo Takahashi, Kazuyuki Shigeno, Yoshinobu Kanda, Naoko Hatsumi, Shigeki Ohtake, Hisashi Sakamaki, Kazunori Ohnishi, Shuichi Miyawaki, Ryuzo Ohno, Tomoki Naoe.   

Abstract

We analyzed the incidence and prognosis of bacteremia/fungemia and pneumonia during remission induction therapy of a newly diagnosed acute myelogenous leukemia (AML) in the Japan Adult Leukemia Study Group treated with individual protocols of AML-87/-89 (1987-1991), AML-92 (1992-1995), AML-95 (1995-1997), and AML-97 (1997-2001). Bacteremia/fungemia was present in 251 of 2585 cases (9.7%); the causative microorganism was gram-positive bacteria (GPB) in 122 cases (49%), gram-negative bacteria (GNB) in 90 cases (36%), fungi (F) in 31 cases (12%), and polymicrobes (P) in 8 cases (3%). Particularly prevalent were Pseudomonas aeruginosa in 49 cases (20%), Staphylococcus epidermidis in 29 cases (12%), and Staphylococcus aureus in 25 cases (10%). With AML-87/-89, incidence of bacteremia/fungemia was 11.8% while it was 9.4% with AML-92, 8.7% with AML-95, and 9.2% with AML-97. The proportion of GPB, GNB, F, and P was 40, 41, 16, and 3% in AML-87/-89, 46, 40, 11, and 3% in AML-92, 48, 39, 11, and 2% in AML-95, and 59, 26, 11, and 4% in AML-97. The mortality rate by period was 26.5, 16.4, 14.0, and 6.8%, respectively. Pneumonia was found in 433 cases (16.8%); microbiological research covered 359 cases of AML-87/-89, AML-92, AML-97 and excluded AML-95 as there was no listing for the causative microorganism on questionnaires. Microbiologically documented pneumonia was found in 123 cases (34.3%), with GPB in 33 cases (27%), GNB in 28 cases (23%), F in 44 cases (36%), and P in 18 cases (15%); particularly prevalent were Aspergillus in 23 cases (19%), Staphylococcus aureus in 16 cases (13%), and Pseudomonas aeruginosa in 15 cases (12%). The incidence of pneumonia overall was 24.6% with AML-87/-89, 16.9% with AML-92, 13.9% with AML-95, and 12.9% with AML-97, with a mortality rate of 28.9, 33.3, 16.7, and 16.7%, respectively. Incidence of bacteremia/fungemia and pneumonia complicating AML has tended to decline in recent years, and mortality has also tended to improve.

Entities:  

Mesh:

Year:  2011        PMID: 21213127     DOI: 10.1007/s12185-010-0746-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  30 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

Review 2.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; J Peter Donnelly; Paul E Verweij
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

3.  Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Leonard Leibovici
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

4.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

5.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.

Authors:  D Caillot; O Casasnovas; A Bernard; J F Couaillier; C Durand; B Cuisenier; E Solary; F Piard; T Petrella; A Bonnin; G Couillault; M Dumas; H Guy
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hitoshi Kiyoi; Yasushi Miyazaki; Hirokazu Okumura; Shin Matsuda; Tadashi Nagai; Yuji Kishimoto; Masaya Okada; Masatomo Takahashi; Hiroshi Handa; Jin Takeuchi; Shinichi Kageyama; Norio Asou; Fumiharu Yagasaki; Yasuhiro Maeda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2010-03       Impact factor: 2.490

7.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.

Authors:  Axel Glasmacher; Archibald Prentice; Marcus Gorschlüter; Steffen Engelhart; Corinna Hahn; Benjamin Djulbegovic; Ingo G H Schmidt-Wolf
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.

Authors:  T Kobayashi; S Miyawaki; M Tanimoto; K Kuriyama; H Murakami; M Yoshida; S Minami; K Minato; K Tsubaki; E Ohmoto; H Oh; I Jinnai; H Sakamaki; A Hiraoka; A Kanamaru; I Takahashi; K Saito; T Naoe; O Yamada; N Asou; S Kageyama; N Emi; A Matsuoka; M Tomonaga; R Ohno
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes.

Authors:  T Obayashi; M Yoshida; T Mori; H Goto; A Yasuoka; H Iwasaki; H Teshima; S Kohno; A Horiuchi; A Ito
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

10.  Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.

Authors:  R Ohno; T Kobayashi; M Tanimoto; A Hiraoka; K Imai; N Asou; M Tomonaga; K Tsubaki; I Takahashi; Y Kodera
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

View more
  12 in total

1.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

Review 2.  Pneumonia in the neutropenic cancer patient.

Authors:  Scott E Evans; David E Ost
Journal:  Curr Opin Pulm Med       Date:  2015-05       Impact factor: 3.155

3.  Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.

Authors:  Shun-Ichi Kimura; Hiroyuki Fujita; Hideaki Kato; Nobuhiro Hiramoto; Naoko Hosono; Tsutomu Takahashi; Kazuyuki Shigeno; Naoko Hatsumi; Hitoshi Minamiguchi; Junichi Miyatake; Hiroshi Handa; Nobu Akiyama; Yoshinobu Kanda; Minoru Yoshida; Hitoshi Kiyoi; Yasushi Miyazaki; Tomoki Naoe
Journal:  Support Care Cancer       Date:  2017-06-06       Impact factor: 3.603

4.  Pneumonia during remission induction chemotherapy in patients with acute leukemia.

Authors:  Javier Barreda Garcia; Xiudong Lei; William Wierda; Jorge E Cortes; Burton F Dickey; Scott E Evans; David E Ost
Journal:  Ann Am Thorac Soc       Date:  2013-10

5.  Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.

Authors:  Hideaki Kato; Hiroyuki Fujita; Nobu Akiyama; Shun-Ichi Kimura; Nobuhiro Hiramoto; Naoko Hosono; Tsutomu Takahashi; Kazuyuki Shigeno; Hitoshi Minamiguchi; Junichi Miyatake; Hiroshi Handa; Yoshinobu Kanda; Minoru Yoshida; Shuichi Miyawaki; Shigeki Ohtake; Tomoki Naoe; Hitoshi Kiyoi; Itaru Matsumura; Yasushi Miyazaki
Journal:  Support Care Cancer       Date:  2018-06-02       Impact factor: 3.603

6.  Inducible epithelial resistance protects mice against leukemia-associated pneumonia.

Authors:  Miguel M Leiva-Juárez; Hayden H Ware; Vikram V Kulkarni; Patrick A Zweidler-McKay; Michael J Tuvim; Scott E Evans
Journal:  Blood       Date:  2016-06-17       Impact factor: 22.113

7.  Fatal Infections Among Cancer Patients: A Population-Based Study in the United States.

Authors:  Yongqiang Zheng; Ying Chen; Kaixu Yu; Yun Yang; Xindi Wang; Xue Yang; Jiaxin Qian; Ze-Xian Liu; Bian Wu
Journal:  Infect Dis Ther       Date:  2021-03-24

8.  Expression of CD200 on AML blasts directly suppresses memory T-cell function.

Authors:  S J Coles; R K Hills; E C Y Wang; A K Burnett; S Man; R L Darley; A Tonks
Journal:  Leukemia       Date:  2012-03-20       Impact factor: 11.528

9.  Bacillus cereus infection in pediatric oncology patients: A case report and review of literature.

Authors:  Sunisha Arora; Dhwanee Thakkar; K Upasana; Anjali Yadav; Neha Rastogi; Satya Prakash Yadav
Journal:  IDCases       Date:  2021-10-05

10.  Deep learning computer-aided detection system for pneumonia in febrile neutropenia patients: a diagnostic cohort study.

Authors:  Eui Jin Hwang; Jong Hyuk Lee; Jae Hyun Kim; Woo Hyeon Lim; Jin Mo Goo; Chang Min Park
Journal:  BMC Pulm Med       Date:  2021-12-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.